Rachit N.

Life Sciences Investor @ General Catalyst

πŸ“ United StatesπŸ”„ Updated October 2026πŸ’Ό 3 investmentsπŸ“… 5 years investingπŸ—“ Last invested Oct 2024
VC🌍 United States
3
Total investments
1
Early stage
0
Mid stage
1
Late stage
5y
Years active

Portfolio

2 investments Β· sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Oct 2024
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
Investor | Life Sciences
Apr 2021
CaaS Capital is a global investment manager that employs a combined fundamental and quantitative approach to investing public and private equity, venture and real estates.
Experience Β· 3 entries
All (3)
Investments (3)
Board (1)
2024
Board Observer
Oct 2024
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
2023
Investor | Life Sciences
Mar 2023
We partner with the world’s most ambitious entrepreneurs to drive resilience and applied AI. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond. With offices in the US, Europe, and India, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Anthropic, Applied Intuition, Commure, Glean, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto. For more information, visit: www.generalcatalyst.com.
2021
Investor | Life Sciences
Apr 2021
CaaS Capital is a global investment manager that employs a combined fundamental and quantitative approach to investing public and private equity, venture and real estates.
Investment activity
2021–2024 Β· 3 investments
202112023120241
Recent (last 2 years)Earlier